Back to mobile site

BMO Capital Reiterates Outperform Rating on Structure Therapeutics (GPCR)

April 23, 2024 2:54 PM EDT Send to a Friend
BMO Capital analyst Evan Seigerman reiterated an Outperform rating and $83.00 price target on Structure Therapeutics (NASDAQ: GPCR).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login